Latest Imprimis Pharmaceuticals Inc. Stories
Study also demonstrated that combination heparin and alkalinized lidocaine formulation yielded higher lidocaine absorption versus lidocaine alone SAN DIEGO, May 18, 2015 /PRNewswire/ -- Imprimis
Management will host conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) SAN DIEGO, May 13, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Introducing the Defeat IC(TM) Education Campaign for Interstitial Cystitis and the ED Free(TM) Education Campaign for Erectile Dysfunction SAN
SAN DIEGO, May 4, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Launch of Hep-Lido-A and the Defeat IC(TM) educational campaign planned for the upcoming American Urological Association Annual Meeting in New Orleans SAN DIEGO, April 28, 2015 /PRNewswire/
Planned ASCRS Symposium events and sessions will highlight Imprimis' Dropless Therapy and Combination Drop Therapy SAN DIEGO, April 15, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
SAN DIEGO, April 2, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Patent-pending ophthalmic formulation fourth quarter 2014 revenues increased by over 101% compared to third quarter 2014 revenues for the same products SAN DIEGO, March 12, 2015 /PRNewswire/
SAN DIEGO, March 4, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.
Investigator reports that Imprimis' combination compounded Tri-Moxi and Pred-Moxi formulations produced equivalent patient outcomes compared to traditional standard of care individual eye drops, while